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SUMMARY
The impact of increasing body mass index (BMI) on development and
progression of chronic kidney disease is established. Even implantation
kidney biopsies from obese living donors demonstrate subtle histologic
changes despite normal function. We hypothesized that kidneys from obese
living (LD) and deceased donors (DD) would have inferior long-term allo-
graft outcomes. In a study utilizing US transplant registry, we studied adult
kidney transplant recipients from 2000 to 2014. Donors were categorized
as BMI <20 (underweight), 20–25 (normal), 25–30 (overweight), 30–35
(mildly obese), and >35 kg/m2 (very obese). Our outcome of interest was
death censored graft failure (DCGF). Cox proportional hazards model were
fitted separately for recipients of DD and LD kidneys, and adjusted for
donor, recipient, and transplant characteristics, including donor and recipi-
ent size mismatch ratio. Among 118 734 DD and 84 377 LD transplants
recipients, we observed a significant and graded increase in DCGF risk
among the overweight (LD:HR = 1.06, DD:HR = 1.04), mildly obese (LD:
HR = 1.16, DD:HR = 1.10), and very obese (LD:HR = 1.22, DD:
HR = 1.22) compared to normal BMI (P < 0.05). The graded effect of
donor BMI on outcomes begins early and persists throughout the post-
transplant period. Donor obesity status is an independent risk factor for
inferior long-term renal allograft outcome despite adjusting for donor and
recipient size mismatch and other donor, recipient, and transplant factors.
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Introduction
The obesity epidemic has reached alarming proportions
and has been linked to the increasing burden of chronic
kidney disease (CKD) in the United States and world-
wide [1,2]. Obesity causes various structural, hemody-
namic, and metabolic alterations in the kidney. Kidneys
from obese individuals have been noted to have
glomerulomegaly (glomerular hypertrophy), focal seg-
mental glomerulosclerosis, and focal podocyte foot pro-
cess effacement together being distinctly named as
“obesity-related glomerulopathy” (ORG) [3,4]. It has
been demonstrated that patients diagnosed with ORG
have an increased risk of progression to end-stage renal
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disease (ESRD) [3,5–7]. The impact of obesity also
extends into the arena of transplantation where obese
kidney transplant recipients have been noted to have
inferior allograft outcomes even after accounting for the
increased risk of all-cause death among the obese [8].
However, the impact of donor body mass index (BMI)
on both living and deceased donor kidney transplant
(KT) outcomes has not been studied systematically.
The exact mechanism(s) behind how obesity leads to
CKD or the observed structural changes in the kidney
remains unknown. Brenner et al. [9] have hypothesized
that a kidney that is small for the metabolic needs of an
individual is likely to experience a triad of glomerular
hypertension, hypertrophy, and hyperfiltration that
eventually leads to progressive glomerulosclerosis, pro-
teinuria, and loss of function. This hypothesis explains
not only the increased risk of ESRD among obese indi-
viduals, but also in kidney transplantation where worse
outcomes have been observed in larger recipients of
smaller donor kidneys. In contrast, smaller recipients of
larger donor kidneys have been associated with better
long-term outcomes [10–12].
However, a number of “larger” kidney donors are
overweight and obese and are likely to have underlying
structural changes in the kidney that would be consistent
with ORG. Indeed, implantation biopsies from living
donors has revealed the presence of increased glomerular
planar surface area (GPSA) and tubular dilatation in
obese versus nonobese donors despite no significant dif-
ference in serum creatinine or iothalamate clearance
[13]. However, whether these structural changes affect
long-term allograft outcomes in recipients remain
unclear. Previous studies evaluating the role of donor
BMI on transplantation outcomes are limited and do
not account for the important role that donor and recip-
ient size mismatch play in allograft outcomes [10–
12,14–,17]. Given the observed structural changes in the
kidneys of obese individuals, we hypothesized that kid-
neys procured from such donors are likely to have worse
outcomes in recipients, independent of the recipient’s
BMI and even after accounting for the donor and recipi-
ent size mismatch, both of which have been indepen-
dently shown to affect long-term allograft outcomes.
Methods
Data source/demographics
The Scientific Registry of Transplant Recipients (SRTR)
database was used for the purpose of this study. The
SRTR data system includes data on all donors, wait-
listed candidates, and transplant recipients in the United
States, as submitted by the members of the Organ Pro-
curement and Transplantation Network (OPTN), and
has been described elsewhere. The Health Resources and
Services Administration (HRSA), U.S. Department of
Health and Human Services provides oversight to the
activities of the OPTN and SRTR contractors.
The study population consisted of first-time kidney-
only transplants between January 01, 2000 and Decem-
ber 31, 2014. All recipients and donors younger than
18 years of age were excluded from the study. The natu-
ral age cutoff to adulthood was chosen with the rationale
that kidneys from younger donors might be more
immunogenic, have higher rates of delayed graft func-
tion (DGF), hyperfiltration injury and increased risk of
vascular and ureteral complications [18–24]. Donors
were initially classified based on their calculated BMI
(kg/m2) at the time of donation. Since there were few
donors with BMI <18.5 kg/m2 or >40 kg/m2, we
grouped all donors as follows: BMI <20 kg/m2 (Under-
weight), 20–24.9 kg/m2 (Normal BMI), 25–29.9 kg/m2
(Overweight), 30–35 kg/m2 (Mildly Obese), and >35 kg/
m2 (Very Obese). Race was categorized as White, Black,
Hispanic, and Other (Asian, American Indian, Alaskan
Native, Native Hawaiian, other Pacific Islander, Multira-
cial etc.) as reported by centers to the OPTN.
The primary outcome of interest, death censored
graft failure (DCGF), was defined as the earlier of re-
transplant or return to dialysis with death as a censor-
ing event. Patients were followed from the date of KT
until the date of graft failure, date of death, or the end
of the observation period (December 31, 2014). Because
of the intrinsic differences between deceased and living
organ donations, we conducted separate but parallel
analyses for the two groups. In addition, as a secondary
objective, we assessed the impact of donor obesity on
all-cause graft failure (where deaths are treated as
events, instead of being censored).
Statistical methods
Our primary objective was to determine if recipients
who received kidneys from obese donors experienced
worse outcomes compared to recipients who received
kidneys from donors of normal BMI. To gain a clearer
understanding of the effect of donor BMI on KT out-
comes, we adjusted for the following standard donor
covariates in addition to donor BMI category for
deceased donors: race, gender, 20 pack-year smoking
history, diabetes status, hypertension status, cerebrovas-
cular cause of death, donation after cardiac death,
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hepatitis C status, age, and serum creatinine at the time
of death. Transplant and recipient factors include the
following: cold ischemia time, transplant date, recipient
age, race, gender, height, weight, most recent PRA, pres-
ence of peripheral vascular disease and chronic obstruc-
tive pulmonary disease, hepatitis C status, diabetes
status, previous diagnoses (polycystic kidney disease,
diabetes, hypertension, etc.), length of dialysis, ABO
blood type, medical condition (ICU/hospitalized/refer-
ence), previous malignancy, and HLA mismatches.
Recipient transplant centers were adjusted using indica-
tor variables (i.e., fixed effects model).
With one exception, the degree of missing data was low
(<10%) across all variables of our data set, including vari-
ables pertinent to the calculation of donor BMI (0.003%
for deceased donor transplants; 7.3% for living donors).
Given the low level of missingness, we singly imputed the
covariate sample median. One outlier in terms of missing-
ness is that 27.5% of living donations was missing cold
ischemic time (CIT). Upon closer look, however, we
observe that CIT, for those observed, is highly skewed.
Over 50% had a cold ischemic time of less than 1 h and
over 75% had a value of less than or equal to 2 h. Because
most directed donor or in-center transplants will realisti-
cally have a CIT of less than 3 h, it is plausible that the
missingness is largely due to clerical oversight (i.e., missing
completely at random). Under these conditions, we
imputed with the median value (1 h).
For living donations, all standard transplant and
recipient factors were the same as those for deceased
donations. However, due to the stringent selection crite-
ria for living donors, information on donor smoking,
diabetes, hypertension, cerebrovascular cause of death,
and hepatitis C status were considered irrelevant.
Hence, the adjusted donor factors only include race,
gender, age, and creatinine.
In addition to the above-mentioned covariates, we
also adjusted our model with a donor to recipient Mos-
teller body surface area difference [25]. This is in
essence an interaction term to account for donor and
recipient body surface area mismatch that have previ-
ously been shown to be independently related to allo-
graft outcomes [10]. Functional form of the Mosteller
body surface area difference was used to visualize and
confirm the general linear trend of the covariate (data
not shown).
To obtain the functional form of donor BMI, we fit a
model with quadratic spline terms (with knots at 25,
27.5, and 30 for deceased donors, and knots at 25 and 30
for living donors) that adjusted for the same confounders
as the model to derive the HR comparing the categorized
BMI. We then plotted the log HR as a function of donor
BMI including 95% confidence intervals, with the refer-
ence (log HR of 0) set to a patient with BMI of 25.
Proportional hazards models were fitted separately to
deceased and living-donor recipients, adjusting for the
afore-listed covariates [26]. Our main covariate of inter-
est, donor BMI, was separated into five categories as
listed above. The reference group was selected to be the
normal weight group (BMI 20–25 kg/m2), and hazard
ratios (HRs) were computed for all other groups com-
pared to the reference group.
We quantified the effect on DCGF of donor BMI
using two metrics. The first was the hazard ratio (HR),
estimated using the Cox models described in the pre-
ceding paragraph. For example, the HR for the donor
BMI 26–30 equals the DCGF hazard (rate) divided by
the DCGF rate of the BMI 20–25 category (i.e., the ref-
erence), considering two hypothetical transplants where
all covariates (aside from donor BMI) are equal. The
second metric was the cumulative hazard ratio, which
we plotted against time since transplant [27]. Unlike the
HR, the cumulative hazard ratio is not assumed to be
constant and, instead, is computed as a process over
follow-up time. Cumulative hazard ratios were esti-
mated through models that adjusted for the same
covariates listed above, but stratified by donor BMI cat-
egory. The two metrics are related in the sense that the
cumulative hazard ratio equals the HR when the former
is constant over time.
Donor and recipient BMI are associated with delayed
graft function (DGF) which, in turn, has been shown to
be associated with allograft survival [28]. Hence, in a
second analysis, we excluded patients that experienced
DGF or had graft losses in the first 7 days, then fitted a
Cox model in this cohort.
All analyses were performed using R version 3.5.1 and
SAS version 9.4.
Results
A total of 118 734 deceased-donor and 84 377 living-
donor KT were included in our analysis. Of these,
21 996 (18.5%) of deceased-donor and 11 497 (13.6%)
of living-donor KT recipients experienced graft failure.
For deceased donations, 21 655 graft failures were
attributed to return to dialysis and 637 to repeat trans-
plantation. These numbers include 296 same-day events
between return to dialysis and re-transplants. Similarly,
for living organ transplants, there were 10 998 and 840
graft failures attributed to returns to dialysis and re-
transplants, with 341 same-day events.
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Demographics of study cohort
Table 1 shows the donor factors of the study population
for both deceased and living donor KT. Deceased
donors had a mean BMI of 27.3 (SD 5.76), while living
donors had a mean BMI of 26.9 (SD 4.49) (Fig. 1).
Compared to deceased donors, living donors tended to
be more overweight (43.7% vs. 34.0%) and obese
(18.0% vs. 16.9%). The mean serum creatinine among
living donors was 0.87 mg/dl (SD 0.26) vs. 1.13 mg/dl
(SD 0.66) among deceased donors at the time of dona-
tion. Delayed graft function was reported in 26.2% of
deceased donor recipients and 3.96% of living kidney
donor recipients.
Differential survival based on donor BMI categories
To determine the overall effect of donor BMI categories
on graft failure, we fitted a Cox regression model
adjusting for standard covariates. Table 2 shows the
subset of cox regression results for donor BMI cate-
gories using the reference category of donor BMI 20–25.
There is a clear stepwise increase in death censored allo-
graft failure with increasing BMI. Notably, even a BMI
<20 kg/m2 in recipients of cadaveric donors was asso-
ciated with increased risk of death censored allograft
failure.
Figure 2 shows the functional form of donor BMI in
both deceased and living data sets. We can see that for
deceased donors, BMI roughly follows a U-shape, where
the parameter estimates (equivalently, hazard ratios) are
highest at the two ends of the BMI. On the other hand,
the functional form of BMI for living donors is roughly
linear, indicating that higher donor BMI leads to a
higher prediction of risk.
To visualize the effect of donor BMI across time we
plotted the cumulative hazard ratio against times since
transplant (Fig. 3). Figure 3a demonstrates that recipi-
ents of kidneys from overweight, mildly obese and very
obese deceased donors have a progressive increase in
the risk of death censored allograft failure that begins
immediately after transplantation and remains elevated
over the life of the transplant compared to the donor in
the reference BMI category.
Similar patterns emerge for recipients of allografts
from overweight, obese and very obese living donors
except when donor BMI was <20 kg/m2 (Fig. 3b). In
kidneys from underweight donors, the hazard rate was
lower compared to reference after 2.5 years post-trans-
plant despite the initial increased risk of allograft fail-
ure. One thing to note is that because Mosteller BSA
difference has been included in the model and predic-
tions are done for donor–recipient pairs with no Mos-
teller BSA difference, workload discrepancies between
donor and recipient kidney systems alone cannot
account for this discrepancy in the cumulative hazard.
Figures S1 and S2 demonstrate effect of donor BMI
across time on all cause graft failure and patterns
remain similar to DCGF models.
When DGF and graft failure within the first 7 days
after kidney transplant were excluded, there was no sig-
nificant difference in our hazard estimates thereby sug-
gesting that the effect of BMI on death censored
allograft survival is likely to be independent of its effect
on DGF (Table 3).
Discussion
In a large cohort of kidney donors and recipients span-
ning a decade and a half, we noted several key findings.
First, we noted a graded, stepwise increase in the hazard






Age 41.98 (14.05) 41.12 (11.38)
Race
White race 71.3% 69.6%
African American race 12.6% 12.7%
Hispanic race 12.9% 13.0%
Asian race 2.3% 3.4%
Other race 0.9% 1.3%
Gender
Female 40.8% 60.2%
Serum creatinine (mg/dl) 1.13 (0.66) 0.87 (0.26)
















0.0073 (0.36) 0.0406 (0.33)
Donor BMI
<20 (lower weight) 6.3% 3.8%
20–25 (normal) 32.5% 30.6%
25–30 (overweight) 34.0% 43.7%
30–35 (mildly obese) 16.9% 18.0%
>35 (very obese) 10.3% 3.9%
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of graft failure in kidneys procured from overweight
and obese donors compared to donors with a normal
body mass index. Importantly, this effect lasted even
after adjustment for donor, recipient, and transplanta-
tion factors including donor and recipient size mis-
match, a phenomenon known to drive long-term
allograft failure. Secondly, we noted that kidneys from
overweight and obese living donors experienced a high
risk of graft loss early after transplantation and while
this risk reduced with time, it remained elevated com-
pared to kidneys from donors with a reference BMI.
Together these data are consistent with the hypothesis
that kidneys from obese (and overweight) donors, as
defined by BMI, likely have underlying structural dam-
age that affects long-term allograft survival.
Two studies have specifically investigated whether
donor BMI was associated with long-term allograft out-
comes. In the first study that analyzed deceased donors
from the UK transplant registry, the authors noted an
association between donor BMI and 12-month crea-
tinine as well as death censored graft survival. However,
this relationship was lost after multivariable adjustment
[14]. While the authors did adjust for recipient BMI,
they did not investigate the interaction between donor
and recipient BMI on outcomes. A second US-based
registry study observed no association between donor
BMI and death censored allograft survival among
organs procured after brain death (DBD). However,
donor BMI of >45 kg/m2 was associated with death
censored allograft outcomes among recipients of organs
after circulatory death (DCD) [16]. Such extremes of
donor BMI are however unusual and these donors are
typically excluded from donation. Additional studies
evaluating the effect of recipient and donor size mis-
match had not specifically tested whether donor BMI
was an independent risk factor for outcomes [12,17]. In
our study, after adjustments for recipient and donor
body size mismatch and multiple additional donor,
recipient, and transplantation factors, we were able to
Figure 1 Distribution of body mass index by donor type
Table 2. (a) Effect of deceased donor body mass index
(BMI) on death censored allograft outcomes. (b) Effect of




ratio 95% CI of HR P-value
(a)
<20 0.100 1.11 1.04, 1.17 0.00061***
25–30 0.036 1.04 1.00, 1.08 0.0525
30–35 0.098 1.10 1.05, 1.16 0.0002***
>35 0.201 1.22 1.14, 1.31 <0.0001***
(b)
<20 0.064 0.94 1.04, 1.17 0.221
25–30 0.058 1.06 1.00, 1.08 0.02*
30–35 0.147 1.16 1.05, 1.16 <0.0001***
>35 0.195 1.22 1.14, 1.31 0.0005***
Multivariable model was adjusted for:
Donor factors: race, gender, age, serum creatinine, BMI cate-
gory.
Deceased only donor factors: diabetes status, hypertension
status, HCV serum positivity, stroke as cause of death, dona-
tion after circulatory death, greater than 20 pack-year
(smoking).
Recipient factors: age, transplant date, race, gender, height,
weight, most recent PRA, comorbidities (peripheral vascular
disease, chronic pulmonary obstructive disorder, diabetes,
hypertension, polycystic kidney disease, other diagnoses),
HCV serum positivity, dialysis length, ABO blood type, pre-
transplant malignancy, working status, medical condition
(ICU/hospitalized/neither).
Transplant factors: HLA mismatches, Mosteller BSA differ-
ence, cold ischemic time, transplant center (by factor).
Reference donor BMI category was 20–25 kg/m2.
* indicates a P-value less than or equal to 0.05
** indicates a p-value less than or equal to 0.01.
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demonstrate a clear graded increased risk of death cen-
sored and all-cause allograft failure among kidneys from
donors who were overweight and obese. Further, donor
DCD or DBD status did not affect this relationship.
The cause of increased risk of allograft failure among
recipients of kidneys with higher donor BMI remains
speculative but at least two pertinent issues are worth
considering. First, it is possible that the increased risk
of graft failure might be due to underlying structural
injury that makes these grafts more prone to the
ischemic, immune and workload insults of kidney trans-
plantation. The second possibility is that the higher risk
of delayed graft function among kidneys from obese
donors might affect long-term outcomes. While a previ-
ous study did not observe an effect of donor BMI on
DGF [28], a recent study of deceased donors from the
British transplant registry noted a higher rate of DGF
among obese donor kidneys. However, this increased
rate of DGF did not translate into a higher risk of long-
term allograft loss or death [14]. Despite this finding,
given the known association of DGF with long-term
allograft survival [29,30] we conducted additional sensi-
tivity analysis excluding patients that had DGF or lost
their grafts within the first 7 days after transplantation
(to reduce the impact of DGF, technical and other
organ complications on long-term outcomes). To our
surprise, even after this exclusion those who received
kidneys from overweight and obese donors continued
to experience a stepwise higher risk of allograft failure
(Table 3). This would suggest that the impact of over-
weight and obese donors on long-term allograft out-
comes is largely independent of the effect of donor BMI
on delayed graft function.
In addition, we noted that the hazard rate of graft
loss over time appears to be higher in the first 1–
2 years post-transplantation in the overweight and
obese groups compared to reference BMI. This
increased hazard rate is especially prominent among
recipients of deceased donor KT, which might be
related to the deleterious immune, ischemia reperfusion
injury and other processes experienced during the pro-
cess of transplantation in comparison to recipients of
living donor kidneys. Interestingly, in recipients of a
deceased donor kidney even a low donor BMI was
associated with a higher risk of graft loss versus refer-
ence donor BMI. Investigations into the possible cause
of graft loss in these individuals were inconclusive due
to the high missing rate of cause of graft loss in our
cohort for that subgroup (>90%). As we excluded
donor age below 18 years of age (thus kidneys should
all be of adult size) these kidney losses are unlikely to
be of a technical nature. Furthermore, we would have
expected any effect of technical nature to have attenu-
ated over time. Even among kidneys from living
donors, we noted an initial increase in graft losses how-
ever this effect was attenuated over time where the haz-
ards of allograft failure appear to be lower than the
reference BMI. Besides the early increase in allograft
loss in recipients of kidneys from underweight deceased
and living donors, the higher risk of long-term allograft
loss among underweight deceased donors remains
unclear but might be related to pathological weight loss
in the donor prior to death and should be an area of
future investigation.
Although kidneys from overweight and obese donors
have inferior outcomes, we do not suggest that such
kidneys not be utilized for organ transplantation. It is
likely that recipients of such organs gain a significant
survival benefit compared with staying on dialysis, but
this hypothesis remains to be tested. It does however
raise questions on potential long-term impact in over-
weight and obese living donors. If recipients of such
kidneys have worse outcomes due to underlying struc-
tural injury to the donor kidney, the remnant kidney
Figure 2 Functional form of donor body mass index (BMI) for
deceased and living donations. Functional form of donor BMI for
both deceased and living donations. Donor BMI was modeled with
quadratic spline terms (with knots at 25, 27.5, and 30 for deceased
donors, and knots at 25 and 30 for living donors) in a model that
adjusted for confounders. Log HR was plotted against donor BMI,
and 95% confidence intervals were included. The reference (log-HR
of 0) was set to a patient with BMI of 25. The donor BMI functional
form for deceased donations follows a U-shape, while the functional
form for living donations is roughly linear.
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in the donor will likely also experience the hyper-
trophic stresses of the one kidney state, minus the
ischemia reperfusion injury, drug toxicity and immune
insults. Further, how postdonation weight gain,
development of hypertension and diabetes after dona-
tion might impact a single kidney state remains unclear
due to lack of granular long-term follow-up data. As
expected by this hypothesis, a recent registry-based
Figure 3 (a) Cumulative hazard ratio (by time since transplant) for death censored allograft failure by donor body mass index (BMI) category.
Deceased donor allografts. Recipients of kidneys from overweight, obese, and very obese cadaveric donors have a graded significantly elevated
risk of death censored allograft loss that begins immediately after transplant and stays elevated compared to recipients who receive kidneys
from cadaveric donors with a normal BMI (solid red line as a reference). In sharp contrast, while kidneys from underweight donors do well very
early after transplantation, this risk appears to increase over time for reasons that remain unclear. (b) Cumulative hazard ratio (by time since
transplant) for death censored donor allograft failure by donor BMI. Living donor allografts. Recipients of kidneys from overweight, obese and
very obese living donors have a graded significantly elevated risk of death censored allograft loss that begins immediately after transplant and
stays elevated compared to recipients who receive kidneys from living donors with normal BMI. For recipients of underweight living donor kid-
ney transplants, the initial risk appears low, becomes high, but falls by the end of the second post-transplantyear.#AuthorQueryReply#
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study demonstrated that by 15-years postdonation,
obese living donors have an increased risk of progres-
sion to ESRD (93 vs. 30, for nonobese donors, per
100 000 donors) [31]. Very long-term outcomes
including the risk of CKD and ESRD among over-
weight and obese donors are expected to be worse but
studies with longer follow-up are needed.
As with any large retrospective study, our study has a
specific focus and several limitations. First of all,
because our primary goal was to show the relationship
between donor BMI and DCGF outcomes, metrics to
measure discrimination or predictive accuracy (such as
the c-index) were therefore not pursued. Various adjust-
ment measures (such as Mosteller BSA and donor BMI)
were included in the model that otherwise would not be
in a model that prioritized risk prediction. Secondly,
the retrospective nature of our study does not allow us
to adjust for unmeasured confounders that could affect
allograft outcomes. Further, our dataset did not have
any histologic parameters of such organs such as
implant biopsy, percentage of global glomerulosclerosis,
glomerular volume, or the health of the tubule-intersti-
tium. In addition, the increased risk of graft failure
among donors with higher BMI does not imply a direct
causal relationship between donor BMI, abnormal his-
tology and allograft failure. Lastly, we did not adjust for
immunosuppression as linked immunosuppression data
were not available. However, since most transplant cen-
ters have fixed immunosuppression protocols, we
believe that adjusting for center effect should have
accounted for immunosuppression effect on our out-
comes of interests.
In summary, we demonstrate that kidneys from over-
weight and obese deceased and living donors are associ-
ated with a graded increased risk for death censored
graft failure after kidney transplantation. Further, this
increased risk starts early and persists throughout the
entire post-transplant period. These data support the
hypothesis that obesity-associated kidney disease in
donors might have a detrimental impact on long-term
allograft outcomes even after accounting for recipient
obesity and donor and recipient size mismatch. Since
the increased risk of allograft failure is also seen in kid-
neys procured from overweight and obese living donors,
our study also offers parallel evidence to support recent
studies that demonstrate increased risk of ESRD among
obese living donors.
Authorship
DES: Participated in study design, acquisition of data
and regulatory approvals, data analysis, and writing of
the paper. ASN: Participated in study design, interpreta-
tion, and writing the first draft of the paper. RP, MD,
SN, YL, ES, VS: Participated in data interpretation, and
writing of the paper. YZ: Participated in data analysis,
interpretation, and writing of the paper.
Funding
The authors have declared no funding.
Conflicts of interest
The authors have declared no conflicts of interest.
Table 3. (a) Effect of deceased donor body mass index
(BMI) on death censored allograft outcomes when
delayed graft function (DGF) patients are excluded. (b)
Effect of living donor BMI on death censored allograft




ratio 95% CI P-value
(a)
<20 0.103 1.11 1.03, 1.19 0.004**
25–30 0.010 1.01 0.96, 1.06 0.665
30–35 0.054 1.06 0.99, 1.13 0.121
>35 0.158 1.17 1.07, 1.28 0.0007***
(b)
<20 0.043 0.96 0.86, 1.07 0.438
25–30 0.045 1.05 0.99, 1.10 0.100
30–35 0.141 1.15 1.07, 1.24 0.0002***
>35 0.166 1.18 1.05, 1.33 0.005**
Multivariable model was adjusted for:
Donor factors: race, gender, age, serum creatinine, BMI cate-
gory.
Deceased only donor factors: diabetes status, hypertension
status, HCV serum positivity, stroke as cause of death, dona-
tion after circulatory death, greater than 20 pack-year (smok-
ing).
Recipient factors: age, transplant date, race, gender, height,
weight, most recent PRA, comorbidities (peripheral vascular
disease, chronic pulmonary obstructive disorder, diabetes,
hypertension, polycystic kidney disease, other diagnoses),
HCV serum positivity, dialysis length, ABO blood type, pre-
transplant malignancy, working status, medical condition
(ICU/hospitalized/neither).
Transplant factors: HLA mismatches, Mosteller BSA differ-
ence, cold ischemic time, transplant center (by factor).
In addition to DGF, any recipient with a follow-up time of
<7 days was also excluded for the purpose of this analysis.
Reference Donor BMI category was 20–25 kg/m2.
** indicates a P-value less than or equal to 0.05
*** indicates a p-value less than or equal to 0.01.
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SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Figure S1. Cumulative Hazard Ratio (by time since
transplant) for total graft failure by Donor BMI cate-
gory. Deceased Donor Allografts.
Figure S2. Cumulative Hazard Ratio (by time since
transplant) for total graft failure by Donor BMI.
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